Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06949800 · ClinicalTrials.gov registry record · Phase 2
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
A Phase 2 study, sponsored by University of California, San Francisco.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT06949800: Clinical Trial Phase 2 study, sponsored by University of California, San Francisco.
NCT06949800 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Francisco. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06949800, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Francisco.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
Primary Outcome
No anal disease defined as complete regression of lesions as determined by examination of biopsies obtained at HRA
Interventions
- DRUG Placebo
- DRUG EXE-346 Probiotic
- PROCEDURE Usual Care High Resolution Anoscopy (HRA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
What is known before NCT06949800 opens enrollment
NCT06949800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06949800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06949800 about?
NCT06949800 is a clinical study titled "CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial". This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
What is the current status of trial NCT06949800?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-06-01. Estimated completion is 2027-05-31.
What interventions are being tested in trial NCT06949800?
The interventions under investigation include: Placebo (DRUG), EXE-346 Probiotic (DRUG), Usual Care High Resolution Anoscopy (HRA) (PROCEDURE).
Who is sponsoring clinical trial NCT06949800?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06949800's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI